Survival Outcomes and Safety of Programmed Cell Death/Programmed Cell Death Ligand 1 Inhibitors for Unresectable Hepatocellular Carcinoma: Result From Phase III Trials

Programmed cell death (PD-1) and programmed cell death ligand 1 (PD-L1) inhibitors have been increasingly used in cancer therapy. The aim of this study was conducted a meta-analysis to assess the efficacy and safety of PD-1/PD-L1 inhibitors in patients with unresectable hepatocellular carcinoma (uHC...

Descripción completa

Detalles Bibliográficos
Autores principales: Zeng, Linyan, Su, Junwei, Qiu, Wenqi, Jin, Xuehang, Qiu, Yunqing, Yu, Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9014721/
https://www.ncbi.nlm.nih.gov/pubmed/35418272
http://dx.doi.org/10.1177/10732748221092924

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9014721/
https://www.ncbi.nlm.nih.gov/pubmed/35418272
http://dx.doi.org/10.1177/10732748221092924

Ejemplares similares